SOUTH SAN FRANCISCO, CA, Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, announced the completion of a $73.8M Series B financing.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.